| Privacy Policy | Terms of Use | Dealer Return and Exchange Policy | Find a Branch Become a PC Dealer
Additionally, it can be used in the management of conditions like chronic fatigue syndrome and to support detoxification pathways
Discussion Although konzo was first described in 1938, the biological mechanisms that contribute to the development of this disease have remained elusive 23
If a provider cannot answer these clearly, that is a reason to pause
Additionally, studies have pointed out that ornithine decarboxylase (ODC) is a potential target for esophageal squamous cell carcinoma treatment, with its inhibitor, difluoromethylornithine (DFMO), undergoing clinical trials for related cancers (He et al., 2017), and has been used in clinical trials for the treatment of pediatric neuroblastoma (Lozier et al., 2015)
Diabetes Care, 48 (7), e93e93